Zacks: MeiraGTx Holdings PLC (NASDAQ:MGTX) Receives Consensus Rating of “Strong Buy” from Analysts
Shares of MeiraGTx Holdings PLC (NASDAQ:MGTX) have earned a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy rating.
Brokers have set a one year consensus target price of $29.00 for the company, according to Zacks. Zacks has also assigned MeiraGTx an industry rank of 66 out of 256 based on the ratings given to related companies.
Several research analysts have recently commented on MGTX shares. Chardan Capital reissued a “buy” rating on shares of MeiraGTx in a report on Tuesday, May 14th. Zacks Investment Research raised MeiraGTx from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Saturday, March 30th. Finally, Barclays boosted their target price on MeiraGTx from $20.00 to $30.00 and gave the stock a “positive” rating in a report on Wednesday, May 15th.
Shares of MGTX traded down $0.07 on Wednesday, hitting $21.21. The company’s stock had a trading volume of 3,391 shares, compared to its average volume of 119,400. The firm has a market capitalization of $698.14 million and a P/E ratio of -4.83. The company has a quick ratio of 6.96, a current ratio of 6.96 and a debt-to-equity ratio of 0.02. MeiraGTx has a fifty-two week low of $7.98 and a fifty-two week high of $24.76. The business has a 50 day moving average price of $21.31.
MeiraGTx (NASDAQ:MGTX) last announced its earnings results on Tuesday, May 14th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.02. The business had revenue of $0.79 million during the quarter.
MeiraGTx Company Profile
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases.
Recommended Story: What impact do institutional investors have on markets?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.